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Abstract/Summary  
Heart failure is an increasingly prevalent disease with high mortality and public health 
burden. It is associated with autonomic imbalance characterized by sympathetic 
hyperactivity and parasympathetic hypoactivity. Evolving novel interventional and 
device-based therapy has sought to restore autonomic balance by neuromodulation. 
Results of preclinical animal studies and early clinical trials have demonstrated its safety 
and efficacy in heart failure. In this review article, we will discuss specific 
neuromodulatory treatment modalities individually—spinal cord stimulation, vagus nerve 
stimulation, baroreceptor activation therapy and renal sympathetic nerve denervation.  
 
Key Points (3–5) 
• Heart failure (HF) is a disease categorized by sympathetic hyperactivity, 
parasympathetic withdrawal and impaired baroreflex control of sympathetic 
activation.  
• Several measures of autonomic modulation either by implanted devices or 
interventions seek to restore the autonomic balance in HF and improve 
outcomes. These measures include spinal cord stimulation, vagus nerve 
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stimulation, baroreceptor activation therapy and renal sympathetic nerve 
denervation.  
• Preclinical work and the majority of early clinical trials demonstrate the benefits of 
these modalities in HF. Additional larger, well-designed, outcome-based clinical 
trials are warranted to verify the results and determine whether these evolving, 
innovative neuromodulation approaches can be recommended to the growing 
population of HF patients. 
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Introduction 
Congestive heart failure (HF), a disease with high mortality and increasing prevalence,1 
is characterized by autonomic imbalance, including decreased parasympathetic tone,2, 3 
hyperactive sympathetic tone4, 5 and impaired baroreflex control of sympathetic activity.6, 
7 Pharmacotherapy attempting to restore the autonomic imbalance with drugs such as 
beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, 
and aldosterone receptor antagonists have been shown to improve survival among HF 
patients and are recommended for HF patients with reduced ejection fraction.1 However, 
the daunting prospect of HF burden and lack of recent breakthroughs in 
pharmacotherapy have led to the investigations of non-pharmacological approaches that 
can favorably modulate the autonomic tone.8-11 In this article, we will discuss the latest 
avenues of research and clinical trials regarding the application of interventional or 
device-based approaches in treating HF through modulating autonomic activity—
specifically, spinal cord stimulation (SCS), vagus nerve stimulation (VNS), baroreflex 
activation therapy (BAT) and renal sympathetic nerve denervation (RSDN). 
 
Spinal Cord Stimulation 
Technical Aspects 
SCS has been used clinically for chronic pain (approved by the FDA in the US), 
peripheral vascular disease and refractory angina (in Europe). The procedure involves 
the subcutaneous placement of an epidural stimulation lead with distal poles at the level 
of T2-T4, which is connected to an implanted pulse generator in the para-spinal lumbar 
region (Figure 1). SCS can be applied at 90% of the motor threshold at a frequency of 
50 Hz and a pulse width of 200 ms for 2 hours at a time, three times a day. It can also be 
applied for longer intervals. 
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Preclinical Research 
Olgin et al. demonstrated that SCS at the level of T1-T2 increased the sinus cycle length 
and prolonged AV nodal conduction. These effects were abolished after transection of 
bilateral cervical vagus nerves but not transection of ansae subclaviae (sympathectomy), 
suggesting the effect of SCS is vagally mediated.12 In a canine model of ischemic HF, 
SCS during transient myocardial ischemia reduced the incidence of spontaneous 
ventricular tachyarrhythmias.13 This antiarrhythmic effect was again associated with 
vagal effects – reduction in sinus rate, prolongation of PR interval and lowering of blood 
pressure. With direct nerve recordings in ambulatory dogs, Garlie et al.14 demonstrated 
that SCS attenuated augmented sympathetic activity from the stellate ganglion following 
myocardial infarction and pacing-induced HF in an animal model similar to the one noted 
below.  
The chronic cardio-protective effect of SCS in HF was best demonstrated by a 
canine study15 from the same investigator group. All canines first underwent foam 
embolization of the left anterior descending artery followed by ventricular tachypacing to 
create an ischemic HF model. Then the animals were equally randomized to 4 groups: 
• SCS (T4 level, 90% motor threshold, 50 Hz, 0.2-ms pulse duration, 2 hours at a time,  
three times daily). 
• Medical therapy (carvedilol + ramipril). 
• Combined SCS and medical therapy. 
• Control group. 
The dogs were followed chronically for 10 weeks. A significant decline in serum 
norepinephrine and brain natriuretic peptide levels along with decrease of ischemic 
ventricular tachyarrhythmias was observed in dogs receiving SCS. Most interestingly, 
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dogs receiving SCS (with or without medical therapy) had greatest improvement of LVEF 
(from 17% to 52%) with reductions in ventricular volume. The improvement persisted 
throughout the treatment period.  
 
Clinical Trials 
Based on the preclinical work, a number of clinical studies sought to assess the efficacy 
and safety of SCS in systolic HF patients (Table 1).16-19  Of those trials the largest is 
DEFEAT-HF with implanted PrimeAdvanced neurostimulator (Medtronic Inc, 
Minneapolis, MN, USA). It is a multicenter, prospective, randomized (3:2 fashion) control 
trial enrolling 66 patients with LVEF ≤ 35%, NYHA class III HF symptoms while on 
optimal medical therapy, narrow QRS duration and a dilated LV.17 The preliminary data 
of six months of follow-up will soon be presented at the 2014 American Heart 
Association scientific sessions. The results of a smaller prospective trial that enrolled 
nine patients with LVEF ≤ 30% and NYHA class III HF symptoms while on optimal 
medical therapy have been published.16 During the 7-month period of follow up, five 
patients had improved symptoms by at least one NYHA class and three were 
unchanged, while no one worsened. Despite the small sample size, this study 
demonstrated the safety and feasibility of SCS in patients with advanced HF. In 
particular, SCS did not affect the functions (sensing, detection and therapy delivery) of 
the implantable cardioverter defibrillator. 
 
Vagus Nerve Stimulation 
Technical Aspects 
Chronic VNS has been used clinically for years for refractory epilepsy and depression.20 
Its use in HF has recently been studied during right cervical VNS. A cuff electrode is 
secured around the vagus about 3 cm below the carotid artery bifurcation. A brief 
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stimulation that reduces heart rate by 10% is performed to ensure the correct 
positioning. The stimulation lead is then tunneled under the skin and over the clavicle to 
join the intracardiac sensing electrode (placed in the right ventricle, to prevent excessive 
bradycardia) and the pulse generator in the subcutaneous pocket in the right 
subclavicular region (Figure 2). The stimulation parameter then follows an up-titration 
protocol to achieve heart rate reduction of 5-10 beats/min without eliciting adverse 
reactions.21, 22 
 
Preclinical Research 
While HF is associated with a decreased vagal activity, decreased vagal activity itself is 
associated with higher mortality among HF patients.23 VNS is thus an attractive idea in 
treating HF. A number of animal studies using rats and dogs have shown that chronic 
VNS improved LV hemodynamics24, 25 and, more importantly, improved survival in HF.26  
With an implanted device to continuously record autonomic nerve activity in ambulatory 
canines, Shen et al.27 observed that chronic VNS led to a significant reduction in 
sympathetic activity from the left stellate ganglion, which may underlie the cardio-
protective property of VNS. Besides, VNS has additional beneficial effects: 
• VNS has been shown to attenuate systemic inflammation.25, 28  
• VNS, via the modulation of nitric oxide,29 may reduce the slope of action potential 
duration restitution curve,30 which is important in the initiation of VF.31  
• VNS can also significantly increase the expression of connexin-43,24 which is down-
regulated in failing human hearts and thereby arrhythmogenic.32  
• VNS has been demonstrated to be associated with its prevention of mitochondrial 
dysfunction during ischemia-reperfusion.33 
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Clinical Trials 
In a recent multi-center, single-arm, open-label pilot study enrolling 32 patients with 
NYHA class II-IV symptoms and LVEF ≤ 35% using Cardiofit system (BioControl Medical 
Ltd, Yehudi, Israel), VNS was found to be safe and tolerable and to improve quality of 
life and LV systolic function.22 The positive result has prompted larger randomized trials 
to examine the efficacy and safety of this treatment modality in patients with severe 
systolic HF (Table 2).34-36 The results of two of these trials were recently presented in the 
European Society of Cardiology Congress 2014 and showed conflicting findings.  
• NECTAR-HF is a prospective, double-blinded, randomized control study that enrolled 
96 patients with NYHA class II-III symptoms and LVEF ≤ 35% and evaluated right-
sided VNS. It failed to demonstrate an improvement in LV end-systolic diameter, the 
primary endpoint, in 6 months’ time.37 However, it did show that VNS was safe and 
able to significantly improve the quality of life. 
• Anthem-HF is a prospective, open-label, randomized control study that enrolled 60 
patients with NYHA class II-III symptoms and LVEF ≤ 40% and evaluated both right-
sided and left-sided VNS. It showed that either right-sided or left-sided VNS was able 
to significantly improve LVEF and reduce LV end-systolic diameter in 6 months’ 
time.38  
The reason for such obvious different results is unclear. One possibility is that different 
types of stimulating protocols and/or equipment utilized in two studies may have 
recruited different types of fibers within the cervical vagus nerve. In fact, cervical vagus 
nerves invariably contain a small percentage of sympathetic nerves.39, 40 Stimulating the 
cervical vagus is actually stimulating a vagosympathetic trunk. Whether that reduces the 
beneficial effects of cervical VNS remains to be determined. Another larger trial, 
INOVATE-HF, with a plan to enroll 650 patients with similar baseline parameters (LVEF 
≤ 40%, NYHA class III symptoms and a dilated LV) is ongoing.34 The results of this trial 
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may determine whether VNS is really beneficial in HF. Of note, INOVATE-HF is the only 
trial of VNS that chose all-cause mortality or unplanned HF hospitalization as the primary 
outcome measure.  
 
Baroreceptor Activation Therapy 
Technical Aspects 
Chronic electrical activation of the carotid baroreflex, known as BAT, has been 
commercially available and tested in patients with resistant hypertension.41, 42 It has 
since been investigated in HF. For the traditional Rheos system (CVRx Inc, Minneapolis, 
MN, USA), the implantation involves surgically exposing both carotid sinuses and 
placing electrodes around the carotid adventitial surface bilaterally. The leads are 
subcutaneously tunneled and connected to an implantable stimulation device placed in 
the subclavian subcutaneous position on the anterior chest wall. The newer generation 
(Barostim neo, also from CVRx Inc) has only one carotid sinus electrode with smaller 
size (Figure 3) that delivers less power and thus allows easier implant and less adverse 
effects. 
 
Preclinical Research 
Normally, activation of the baroreceptors within the carotid sinuses by an increase in 
aortic pressure or volume sends impulses to the medulla that lead to restoration of 
pressure homeostasis by decreasing efferent sympathetic activity while increasing 
efferent parasympathetic activity,43 both desirable in HF. Furthermore, defective 
baroreflex control of the heart rate in the failing heart has long been recognized.44 
Therefore, BAT has the potential to benefit HF patients and has been studied in an 
experimental HF model. In a microembolization canine model of HF, chronic BAT 
significantly increased LV systolic function and reduced plasma norepinephrine.45 In 
10 
 
another study using rapid pacing model of HF, chronic BAT reduced LV filling pressure, 
decreased plasma norepinephrine and doubled survival duration.46 
 
Clinical Trials 
A recent single-center, open-label, single-arm study enrolled eleven patients with LVEF 
≤ 40% and NYHA class III HF symptoms while on optimal medical therapy that received 
BAT for 6 months.47 Chronic BAT was associated with significant improvement in 
baroreflex sensitivity, LVEF, NYHA class, quality of life and 6-min walk distance, along 
with significant decrease in muscle sympathetic activity. Larger clinical trials are 
ongoing48-50 and summarized in Table 3. Of note, the Rheos HOPE4HF trial48 is one of 
few trials of new treatment modalities evaluating HF with preserved ejection fraction (or 
diastolic HF, LVEF ≥ 40%) population.51 
 
Renal Sympathetic Nerve Denervation 
Technical Aspects 
Catheter-based RSDN is most widely applied clinically as a treatment for resistant 
hypertension.52, 53 Beyond blood pressure, RSDN may prove beneficial in other diseases 
associated with sympathetic hyperactivity, including HF.54 Prior to the procedure, careful 
evaluation by imaging of the renal artery anatomy along with renal function tests is 
warranted to assess suitability of the intervention.55 Via a standard femoral artery 
access, a flexible endovascular electrode catheter connected to a generator is placed 
within the renal arteries to allow delivery of radiofrequency energy. A series of lesions 
along each renal artery then are delivered to disrupt the renal nerves located in the 
adventitia of the renal arteries. For safety reasons, each lesion should be at least 5 mm 
apart. 
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Preclinical Research 
RSDN ablates both efferent and afferent renal sympathetic nerves as they run together, 
with higher nerve density in the proximal segments and ventral region.56 By ablating the 
efferent nerves, RSDN decreases the renal norepinephrine spillover by 47%57 and 
attenuates the activity of renin-angiotensin-aldosterone system,58 both important in the 
pathogenesis of LV remodeling in HF. More importantly from a cardiac standpoint, 
afferent RSDN leads to decreased feedback activation to the central nervous system 
and thereby decreased sympathetic input to the heart (Figure 4). In a murine model of 
ischemic HF, RSDN is associated with reduced LV filling pressure and improved LVEF 
after 4 weeks of follow up.59 Among patients with resistant hypertension, RSDN leads to 
a reduction in heart rate and atrioventricular conduction,60 and, in another study, 
reduction of LV mass, reduction of LV filling pressure, shortening of isovolumic 
relaxation time and increase of LVEF.61 
 
Clinical Trials 
The first trial examining the safety of RSDN in HF patients is REACH-Pilot trial.62 In the 
seven patients with chronic systolic HF and normotension prior to the procedure, there 
were no hypotensive or syncopal events over a 6-month follow-up period. The renal 
function remained stable. Although limited in size, the pilot study showed that there was 
a trend towards an improvement in symptoms and exercise capacity. The encouraging 
results call for larger randomized trials to validate the efficacy and safety of this modality 
in HF, despite the failure of a recent prospective, randomized, blinded study 
(SIMPLICITY HTN-3) to demonstrate any benefit of RSDN in patients with resistant 
hypertension.63 Several larger ongoing trials64-68 are summarized in Table 4. 
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Evolving technology  
Recent preclinical work from the Cleveland Clinic demonstrated that epivascular69 and, 
more excitingly, endovascular70 cardiac plexus stimulation can increase LV contractility 
without increasing heart rate. This was achieved by stimulating the cardiac plexus 
between the ascending aorta and right pulmonary artery. It is known that cardiac 
ganglionated plexi concentrated in epicardial fat pads play a cardinal role in coordinating 
complex interactions between extrinsic and intrinsic cardiac autonomic nervous system71 
and contain highly co-localized sympathetic and parasympathetic ganglion cells.72, 73 The 
idea that stimulating cardiac plexus endovascularly can improve LV contractility is 
fascinating, given that the technique is simple, requiring the placement of a stimulation 
catheter in the right pulmonary artery similar to that of a Swan-Ganz catheter.  In 
addition, chronic stimulation of the cardiac plexus may help restore the impaired 
endogenous nerve activity from the plexus in HF.74 
 
Summary 
HF is increasingly common and remains deadly, despite guideline-based optimal 
medical therapy.1 Most currently available interventional and device-based treatment 
modalities for HF (defibrillator, ventricular assist device or heart transplantation) are 
often “fallbacks” instead of disease-modifiers. The new modalities discussed in the 
present article – SCS, VNS, BAT and RSDN, however, have several distinct features: 
• They seek to correct one of the fundamental impairments of HF – autonomic 
imbalance, which may underpin the survival benefits of beta-blockade and inhibition 
of renin-angiotensin-aldosterone system. One must remember, however, that beta-
blockade is just blockade of beta receptors. That leaves alpha receptors unaffected 
(except perhaps with carvedilol), and does not capitalize on all the other benefits of 
device-based neuromodulation. 
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• Through the same neuromodulation mechanisms, they help prevent the occurrence 
of ventricular tachyarrhythmias,75 which remain a common cause of death in HF 
populations. 
• Unlike previous device-based therapy such as implantable cardioverter defibrillator 
or cardiac resynchronization therapy that focus on HF with reduced ejection fraction, 
some of the ongoing trials with new modalities (Rheos HOPE4HF for BAT, 
DIASTOLE, RDT-PEF and RESPECT-HF for RSDN) enroll patients with HF with 
preserved EF, a population that continues to grow and may overtake HF with 
reduced EF in the near future.76  
• An attractive feature of these new modalities is that they are not “new” to the medical 
practice and have been applied to other indications for years. Their application for a 
new indication therefore should be easier and safer.  
Nonetheless, caution should be exercised when examining the ongoing trials of new 
modalities for HF. In addition to the inherent difficulty of ensuring “true double-blindness” 
of these interventional and device-based treatment modalities, a major criticism is that 
the majority of the completed and ongoing trials have used “soft endpoints” such as 
changes in echocardiographic findings or peri-procedural safety issues rather than “hard 
endpoints” such as cardiovascular mortality or HF event that requires hospitalization. 
Furthermore, as MOXCON trial demonstrated, moxonidine, an antihypertensive agent, 
despite reducing central sympathetic nerve activity and circulating norepinephrine 
concentrations, caused excessive mortality in HF patients and led to early termination of 
the trial.77 This suggests that generalized sympathetic inhibition in HF may be harmful. In 
contrast, results of completed trials of the new modalities have so far been encouraging. 
The mechanisms of neuromodulation of these new modalities are perhaps more 
complex and not just anti-sympathetic. Altogether, autonomic modulation through 
interventions and devices in HF looks promising. It remains to be seen whether these 
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new modalities can be recommended to ever growing population of HF patients pending 
results from larger randomized trials and further investigations. 
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Trial N Criteria Design Endpoint* Status#
Neurostimulation 
of Spinal Nerves 
That Affect 
the Heart
9 • LVEF ≤ 30%• NYHA III
Randomized, 
double-blind, 
crossover
Safety, device 
interactions, 
symptoms
Results 
published 
(see text)
DEFEAT-HF 66
• LVEF ≤ 35%
• NYHA III
• Narrow QRS
• Dilated LV
Randomized, 
single-blind, 
parallel 
Δ in LV 
volume
Active, not 
recruiting. 
Prelim
result soon 
be 
presented.
SCS HEART 20
• LVEF 20-35%
• NYHA III-IV
• Dilated LV
Single-arm, 
open label
Safety, Δ in LV
function, 
exercise 
capacity, QoL
Recruiting
TAME-HF 20
• LVEF ≤ 35%
• NYHA III
• Narrow QRS
Single-arm, 
open label
Δ in LV 
volume,
symptoms, 
exercise 
capacity
Recruiting
 
Table 1. Clinical trials of Spinal Cord Stimulation in Heart Failure. Abbreviations: 
DEFEAT-HF, Determining the Feasibility of Spinal Cord Neuromodulation for the 
Treatment of Chronic Heart Failure; SCS HEART, Spinal Cord 
Stimulation For Heart Failure; TAME-HF, Trial of Autonomic neuroModulation for 
trEatment of Chronic Heart Failure; LVEF, left ventricular ejection fraction; NYHA, New 
York Heart Association; QoL, quality of life. * Only primary outcome measures listed. # 
As of October 2014. 
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Trial N Criteria Design Endpoint* Status#
CardioFit™ for 
the Treatment 
of Heart Failure
32 • LVEF ≤ 35%• NYHA II-IV
Single-arm, 
open label
All adverse 
events
Results 
published 
(see text)
INOVATE-HF 650
• LVEF ≤ 40%
• NYHA III
• Dilated LV
Randomized, 
open label, 
parallel 
All-cause 
mortality or 
unplanned HF 
hospitalization
Recruiting
NECTAR-HF 96
• LVEF ≤ 35%
• NYHA II-III
• Dilated LV
Randomized, 
double-blind, 
crossover
Δ in LV 
volume, 
all-cause 
mortality
Results 
published
(see text)
ANTHEM-HF† 60
• LVEF ≤ 40%
• NYHA II-III
• Dilated LV
Randomized, 
open label, 
parallel 
Δ in LV 
functions, 
adverse 
events
Results 
presented
(see text)
 
Table 2. Clinical trials of Vagus Nerve Stimulation in Heart Failure. Abbreviations: 
INOVATE-HF, INcrease Of VAgal TonE in CHF; NECTAR-HF, Neural Cardiac Therapy 
for Heart Failure Study; ANTHEM-HF, Autonomic Neural Regulation Therapy to 
Enhance Myocardial Function in Heart Failure. * Only primary outcome measures listed. 
# As of October 2014. † Also test left-sided VNS. 
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Trial N Criteria Design Endpoint* Status#
The study by
Gronda et al. 
from Italy
11 • LVEF ≤ 40%• NYHA III
Single-arm, 
open label
Δ in muscle
sympathetic 
activity
Completed
. Results 
published 
(see text)
Rheos
HOPE4HF 540
• LVEF ≥ 40%
• Symptomatic
• Hypertensive
Randomized, 
open label, 
parallel 
CV death or 
HF event, all
adverse 
events
Active, not 
recruiting
XR-1 
Randomized 
Heart Failure 
study
150 • LVEF ≤ 35%• NYHA III
Randomized, 
open label, 
parallel 
Δ in LVEF Active, not recruiting
Barostim
HOPE4HF 60
• LVEF ≤ 35%
• NYHA III
Randomized, 
open label, 
parallel 
Δ in HF 
metric, all 
adverse 
events
Active, not 
recruiting
 
Table 3. Clinical trials of Baroreflex Activation Therapy in Heart Failure. * Only 
primary outcome measures listed. # As of October 2014. 
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Trial N Criteria Design Endpoint* Status#
REACH-Pilot 7 • Chronic HF• NYHA III-IV
Single-arm, 
open label Safety study
Completed. 
(see text)
SymplicityHF 40
• LVEF < 40%
• NYHA II-III
• GFR 30-75
Single-arm, 
open label Safety study Recruiting
Renal 
Denervation in 
Patients With 
Chronic Heart 
Failure
100
• LVEF10-40%
• NYHA II-III
• GFR > 30
Randomized, 
open label, 
parallel 
Safety, number of 
comliplications
Not yet 
recruiting
DIASTOLE 60
• HF symptoms
• LVEF ≥ 50%
• Evidence of HFpEF
• HTN
• GFR > 30
Randomized, 
open label, 
parallel 
Change in E/E' Recruiting
RDT-PEF 40
• LVEF > 40%
• NYHA II-III
• Evidence of HFpEF
Randomized, 
open label, 
parallel 
Change in 
symptoms and 
echo findings
Recruiting
RESPECT-
HF 144
• LVEF ≥ 50%
• NYHA II-IV
• Evidence of HFpEF
• Episode of ADHF
Randomized, 
open label, 
parallel 
Change in LA 
volume index
Recruiting
 
Table 4. Clinical trials of Renal Sympathetic Nerve Denervation in Heart Failure. 
Abbreviations: REACH-Pilot, Renal Artery Denervation in Chronic Heart Failure; 
SymplicityHF, Renal Denervation in Patients With Chronic Heart 
Failure & Renal Impairment Clinical Trial; DIASTOLE, Denervation of 
the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction; RDT-
PEF, Renal Denervation in Heart Failure With Preserved Ejection Fraction; RESPECT-
HF, Renal Denervation in Heart Failure Patients With Preserved Ejection Fraction. * 
Only primary outcome measures listed. # As of October 2014. 
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Figure Legends 
Figure 1. Spinal Cord Stimulation (SCS). A. Schematic representation of SCS system. 
B. X-ray image showing the placement of the SCS lead with concurrent cardiac 
resynchronization therapy-defibrillator (CRT-D) device and leads. (From Torre-Amione 
G, Alo K, Estep JD, et al. Spinal cord stimulation is safe and feasible in patients with 
advanced heart failure: early clinical experience. Eur J Heart Fail 2014;16(7):788-795; 
with permission.) 
 
Figure 2. Vagus Nerve Stimulation (VNS). A. Schematic representation of VNS 
system. (From Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation 
in patients with advanced heart failure: first experience in man. Eur J Heart Fail 
2008;10(9):884-891; with permission.) B. X-ray image showing the placement of the 
VNS stimulator with a previously implanted implantable cardioverter defibrillator (ICD). 
(From Singh JP, Kandala J, Camm AJ. Non-pharmacological modulation of the 
autonomic tone to treat heart failure. Eur Heart J 2014;35(2):77-85; with permission.)  
 
Figure 3. Baroreceptor Activation Therapy (BAT). A. Schematic representation of 
BAT system. The new generation, Barostim neo, is shown here with one carotid sinus 
nerve stimulator (Panel B) that carries one electrode connected to the patch electrode 
(Panel C) that will be fixed to the carotid sinus nerve. (From Kuck KH, Bordachar P, 
Borggrefe M, et al. New devices in heart failure: an European Heart Rhythm Association 
report: developed by the European Heart Rhythm Association; endorsed by the Heart 
Failure Association. Europace 2014;16(1):109-128; with permission.)  
 
Figure 4. Renal Sympathetic Nerve Denervation (RSDN). Physiological and 
pathophysiological actions of renal sympathetic afferent and efferent nerves can be 
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blocked by RSDN. (From Krum H, Sobotka P, Mahfoud F, et al. Device-based 
antihypertensive therapy: therapeutic modulation of the autonomic nervous system. 
Circulation 2011;123(2):209-215; with permission.)  
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